SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS)

Q: What does CUSIP 78397T202 represent in this 13F holders report?

CUSIP 78397T202 is the security identifier for SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share in Q1 2026?

9 institutional investors reported SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share for Q1 2026. Use the holders table for investor-level position and value details.

CUSIP: 78397T202

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 67,297,118
Total 13F shares: 949,660
Share change: +395,749
Total reported value: $3,637,480
Price per share: $3.83
Number of holders: 9
Value change: +$1,515,722
Number of buys: 5
Number of sells: 2

Quarterly Holders Quick Answers

What is CUSIP 78397T202?
CUSIP 78397T202 identifies SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 78397T202:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Vivo Opportunity Fund Holdings, L.P.	13D/G	—	10%	25,931,000	$54,973,720	$0	29 Sep 2025	13D/G
Vivo Capital, LLC	13F	Company	17%	11,420,000	$42,710,800	—	31 Dec 2025	13F
RA CAPITAL MANAGEMENT, L.P.	13D/G 13F	Company	9.9%	7,311,225	$30,195,359	+$8,858,028	19 Mar 2026	13D/G 13F
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	9.1%	4,761,906	$18,761,910	-$1,598,505	31 Dec 2025	13D/G
Commodore Capital LP	13F 13D/G	Company	9.9% from 13D/G	4,401,500	$16,461,610	—	31 Dec 2025	13F 13D/G
Woodline Partners LP	13D/G 13F	Company	9.9%	7,125,881	$14,323,021	$0	30 Sep 2025	13D/G 13F
PERCEPTIVE ADVISORS LLC	13D/G 13F	Company	7.3%	3,471,861	$13,088,916	$0	14 Jan 2026	13D/G 13F
Edward D. Hamilton	3/4/5	10%+ Owner	— mixed-class rows	9,456,382 mixed-class rows	$9,348,396	—	22 Oct 2021	3/4/5
Spruce Street Capital LP	13F	Company	3.3%	2,198,502	$8,222,397	—	31 Dec 2025	13F
Sessa Capital IM, L.P.	13F	Company	3.3%	2,198,457	$8,222,229	—	31 Dec 2025	13F
Blackstone Inc.	13F	Company	3.2%	2,143,585	$8,017,008	—	31 Dec 2025	13F
VANGUARD GROUP INC	13F	Company	2.7%	1,847,136	$6,908,288	—	31 Dec 2025	13F
RTW INVESTMENTS, LP	13D/G	—	3.2%	1,587,302	$6,253,970	+$2,218,090	31 Dec 2025	13D/G
Andrew Moin	3/4/5	Director	— mixed-class rows	2,523,807 mixed-class rows	$3,847,299	—	29 Sep 2025	3/4/5
Sessa Capital (Master), L.P.	3/4/5	Director	— mixed-class rows	2,523,807 mixed-class rows	$3,847,299	—	29 Sep 2025	3/4/5
Ilan Katz	3/4/5	Director, 10%+ Owner	— class O/S missing	3,049,325	$2,683,406	—	13 Oct 2021	3/4/5
Propel Bio Management, LLC	13F	Company	0.97%	652,881	$2,441,775	—	31 Dec 2025	13F
Jefferies Financial Group Inc.	13F	Company	0.86%	580,328	$2,170,427	—	31 Dec 2025	13F
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	0.71%	475,439	$1,778,142	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.48%	324,090	$1,212,097	—	31 Dec 2025	13F
HB Wealth Management, LLC	13F	Company	0.46%	307,500	$1,150,050	—	31 Dec 2025	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.42%	283,645	$1,060,833	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	0.35%	236,460	$884,360	—	31 Dec 2025	13F
Simplify Asset Management Inc.	13F	Company	0.31%	208,227	$778,769	—	31 Dec 2025	13F
AWM Investment Company, Inc.	13F	Company	0.3%	200,000	$748,000	—	31 Dec 2025	13F
STEMPOINT CAPITAL LP	13F	Company	0.22%	146,558	$548,127	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.18%	119,517	$447,037	—	31 Dec 2025	13F
ExodusPoint Capital Management, LP	13F	Company	0.13%	86,113	$322,063	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.08%	51,348	$192,042	—	31 Dec 2025	13F
Pathstone Holdings, LLC	13F	Company	0.08%	50,650	$189,433	—	31 Dec 2025	13F
Alexandra Kropotova	3/4/5	CHIEF MEDICAL OFFICER	— mixed-class rows	2,443,296 mixed-class rows	$178,812	—	24 Mar 2026	3/4/5
OMERS ADMINISTRATION Corp	13F	Company	0.06%	42,000	$157,080	—	31 Dec 2025	13F
Qube Research & Technologies Ltd	13F	Company	0.05%	31,147	$116,490	—	31 Dec 2025	13F
CITIGROUP INC	13F	Company	0.04%	29,974	$112,103	—	31 Dec 2025	13F
Verition Fund Management LLC	13F	Company	0.04%	26,867	$100,483	—	31 Dec 2025	13F
ADAR1 Capital Management, LLC	13F	Company	0.04%	26,344	$98,527	—	31 Dec 2025	13F
Persistent Asset Partners Ltd	13F	Company	0.03%	19,790	$74,015	—	31 Dec 2025	13F
Focus Partners Wealth	13F	Company	0.03%	19,201	$71,812	—	31 Dec 2025	13F
First PREMIER Bank	13F	Company	0.03%	18,986	$71,000	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.03%	17,650	$66,011	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	0.03%	17,239	$64,474	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.02%	16,412	$61,381	—	31 Dec 2025	13F
FIFTH LANE CAPITAL, LP	13F	Company	0.02%	15,000	$56,100	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.02%	13,122	$49,076	—	31 Dec 2025	13F
Kestra Advisory Services, LLC	13F	Company	0.02%	11,550	$43,197	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	— mixed-class rows	10,713 mixed-class rows	$39,696	—	31 Dec 2025	13F
CAXTON CORP	13F	Company	0.02%	10,527	$39,371	—	31 Dec 2025	13F
State of Wyoming	13F	Company	0.01%	8,971	$33,552	—	31 Dec 2025	13F
UBS Group AG	13F	Company	— mixed-class rows	13,584 mixed-class rows	$27,860	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	— mixed-class rows	150,701 mixed-class rows	$20,509	—	31 Dec 2025	13F

Institutional Holders of SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) as of Q1 2026

As of 31 Mar 2026, SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) was held by 9 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 949,660 shares. The largest 9 holders included HB Wealth Management, LLC, SEVEN GRAND MANAGERS, LLC, Simplify Asset Management Inc., Kestra Advisory Services, LLC, UBS Group AG, COMMONWEALTH EQUITY SERVICES, LLC, First PREMIER Bank, Plante Moran Financial Advisors, LLC, and GS Investments, Inc.. This page lists 9 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

Q1 2026 holders

Holder diff

-39

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.